Navigation Links
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
Date:12/11/2009

e AC220 from concept to lead candidate selection in only 18 months.

About Acute Myeloid Leukemia (AML)

Acute myeloid leukemia is a form of blood cancer. According to the American Cancer Society, approximately 13,000 new cases of AML will be diagnosed in the United States in 2008. The median age of a patient with AML is about 67 years. Standard treatment for patients 60 years or older with AML includes systemic combination chemotherapy. The median survival for patients receiving induction chemotherapy, which is associated with high mortality, is 6-11 months, with shorter survival for patients over the age of 60 years. The five-year survival rate for AML is less than 15 percent due to refractory and relapsed disease associated with standard treatments. According to a report from Decision Resources, the U.S. AML market is expected to more than double by 2015.

About Ambit Biosciences

Ambit Biosciences is a privately-held biopharmaceutical company engaged in the discovery and development of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease, and other indications. Ambit employs a novel and proprietary kinase profiling technology, KINOMEscan(TM), to screen compounds against 442 human kinases.

Ambit's lead compound, AC220, is in clinical development for the treatment of AML and other indications. Ambit plans to commence in 2009 and 2010 several clinical studies with AC220, including a registration study in AML. Ambit's clinical pipeline also includes AC480, an oral pan-HER inhibitor that was in-licensed from BMS. Ambit is conducting Phase 2 studies with AC480 in patients with solid tumor cancers. Additionally, Ambit has an advancing pool of preclinical candidates targeting BRAF (in collaboration with Cephalon), JAK2, Aurora, and CSF1R. Through its KINOMEscan Division, Ambit markets its technology as a profiling service. For more information, visit '/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
2. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
3. Cell Biosciences Acquires Protein Forest
4. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
5. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
6. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
7. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
8. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
9. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  BioClinica®, Inc., ... technology provider, today announced that clinical trial ... convened at its annual European User Conference ... to discuss the use of its eClinical ... eClinical technologies include: the Microsoft Office-Smart OnPoint ...
(Date:3/4/2015)... March 4, 2015 Launched ... Paris in December 2011, ,SARAH, - ... resin microspheres versus sorafenib in advanced hepatocellular carcinoma (HCC) ... 2016.   SARAH, a large French study ... carcinoma, or HCC) has completed patient enrolment, exceeding its ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
(Date:3/3/2015)... Ky. (PRWEB) March 03, 2015 Experts ... their schedules for one event: the Alltech REBELation exploring ... from May 17-20. Now in its 31st year, Alltech’s ... from 70 countries, and the opportunity to join the ... March 7 at 11:59 p.m. EST, at which point ...
Breaking Biology Technology:BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... Mass. and CHICAGO, March 29 Boston,Scientific Corporation ... an analysis,of two-year data from more than 7,000 ... was designed to evaluate the safety performance of ... in "real-world" practice. Outcomes through two years in ...
... MINRAD,International, Inc. (Amex: BUF ) today announced its ... as President and Chief,Operating Officer, effective April 1, 2008, ... Company. Mr. DiGiacinto,s appointment is the,first step in a ... the Company beginning on January 1, 2009. William H. ...
... Aerovance Inc. today,announced it has secured $20 ... the syndicate, which includes Silicon Valley Bank,and Comerica ... financing line,at closing. The remaining $10 million is ... financing reflects continued interest and enthusiasm in Aerovance,and ...
Cached Biology Technology:Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 2Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 3Real-World Data from ARRIVE Registries Show Favorable Outcomes for TAXUS(R) Express(TM) Stent 4MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer 2MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer 3MINRAD International, Inc. Announces Appointment of David T. DiGiacinto as President and Chief Operating Officer 4
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ... "Global Biometrics Market Forecast and Opportunities, 2020" ... for biometric authentication systems is projected to grow ... The driving forces for this highly ... projects and constant development in technology. In 2014, ...
(Date:3/2/2015)... 2015   Neurotechnology , a provider of high-precision ... SentiGaze Software Development Kit (SDK). The SentiGaze algorithm ... off-the-shelf webcams to track eye movements and generate heatmaps ... Heatmaps can be used for applications such as analysis ... The SDK can also be used to develop interfaces ...
(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2
... J. Fox Foundation for Parkinson,s Research today announced ... research teams under its Target Validation initiative. This ... to help push potential PD drug targets forward ... million Parkinson,s patients worldwide. "The discovery of ...
... account for almost 50% of crop sales in the ... ensure good quality. But more information is needed about ... changes so that management practices such as irrigation can ... generalize because of variations in crops, planting densities, and ...
... The AIDS Vaccine Advocacy Coalition (AVAC) today urged Dr. Anthony ... Diseases (NIAID) to act swiftly to clarify the path ahead ... with the proposed PAVE 100 AIDS vaccine trial but would, ... also calls on leaders in the field to make clear ...
Cached Biology News:Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinson's 2Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinson's 3Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinson's 4Digital cameras, remote satellites measure crop water demand 2AVAC comments on NIAID decision not to move forward with PAVE 100 Trial 2AVAC comments on NIAID decision not to move forward with PAVE 100 Trial 3
A Highly Purified, Cost-Effective Taq DNA Polymerase...
...
... Neogens enzyme-linked immunosorbent assay (ELISA) ... as screening devices for the detection of ... The kits are intended for forensic use ... samples be confirmed by a quantitative method ...
96 Well Base Plate...
Biology Products: